ReviewJournal of the renin-angiotensin-aldosterone system : JRAAS2022
Cardiorenal Disease in COVID-19 Patients.
Review in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Effects of innovative modular prone positioning tools in patients with acute respiratory distress syndrome due to COVID-19 during awake prone position: a prospective randomized controlled trial.European journal of medical research · 2024Trial
- Association between hypertension and risk of respiratory failure and mortality in patients with COVID-19: a retrospective cohort study with predictive model development.Frontiers in medicine · 2026Article
- Safety and efficacy of endoscopy-guided nasojejunal feeding tube placement in ICU post-COVID-19 patients: a retrospective study.European journal of medical research · 2025Article
- Impact of prophylactic anticoagulation on hospitalized COVID-19 patients aged over 80 years: a multicenter prospective cohort study.European journal of medical research · 2025Article
- Impact of COVID-19 on door-to-wire time in ST-segment elevation myocardial infarction treatment: the role of digital communication.BMC cardiovascular disorders · 2025Article
- Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough.European journal of medical research · 2025Article
- Analysis of risk factors for benign central airway stenosis after COVID-19 infection.European journal of medical research · 2024Review
- Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation.European journal of medical research · 2024Article
- Vascular Implications of COVID-19: Role of Radiological Imaging, Artificial Intelligence, and Tissue Characterization: A Special Report.Journal of cardiovascular development and disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Mutations in the genetic coding and the variations in the spike proteins are critical for the virus's mechanism of facilitating fusion with the human host, making the disease more severe. Recent research indicates that comorbidities including diabetes, hypertension, renal disease, heart failure, and atherosclerosis play a significant role in the severity and high mortality rates of (COVID-19), suggesting that perhaps the metabolic syndrome and its components are associated with COVID-19 morbidity. Primarily, angiotensin-converting enzyme 2 (ACE2) receptor is identified as the entrance receptor of SARS-CoV-2. Increased ACE2 expression, endothelial dysfunction plays a vital role in the progression and severity of complications developed due to COVID-19. In this review, we will discuss the association and management of cardiorenal disease and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.